XASX
CGS
Market cap403mUSD
Oct 09, Last price
3.45AUD
1D
1.17%
1Q
18.97%
Jan 2017
184.22%
IPO
608.81%
Name
CogState Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cogstate Limited, a neuroscience technology firm established in 1999 and headquartered in Melbourne, Australia, specializes in digital cognitive assessments and electronic solutions for evaluating clinical outcomes. The company offers a comprehensive suite of cognitive services, encompassing project and data management, scientific consulting, statistical interpretation, acquisition of assessment tools, rater training, and monitoring solutions. It operates through two primary divisions: Clinical Trials and Healthcare. The Clinical Trials segment delivers specialized technology and related support to pharmaceutical and biotechnology companies, enabling them to precisely measure the impact of diseases, medications, medical devices, or other interventions on human participants in clinical studies. Conversely, its Healthcare division supplies Cognigram, a standardized and routine testing system designed to assist primary care providers and hospitals in the early identification of cognitive impairment. As of June 30, 2022, Cogstate had contributed to approximately 1,800 academic research endeavors.
Key people
Martyn Myer
Non-Executive Chairman of the Board
Darren Watson
Chief Financial Officer · since 2021
Rachel Colite
Executive Vice President - Clinical Trials · since 2023
Chris Edgar
Chief Scientific Officer · since 2022
Brad O'Connor
Chief Executive Officer, Managing Director, Executive Director · since 2005
Kaycee Sink
Chief Medical Officer · since 2024
Company Secretary · since 2022
Kristi Geddes
General Counsel, Joint Company Secretary · since 2023
Richard Mohs
Independent Non-Executive Director · since 2021
Independent Non-Executive Director · since 2019
Kim Wenn
Independent Non-Executive Director · since 2020
Headquarters & legal address
LEVEL 2
161 COLLINS ST
MELBOURNE, VIC 3000
AU
161 COLLINS ST
MELBOURNE, VIC 3000
AU
Previous name
EXAMINATION SERVICES FOR PSYCHOLOGY LIMITED
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||